Daito Pharmaceutical Completes 1 Million-Share Buyback to Bolster Shareholder Returns

Daito Pharmaceutical Co., Ltd. ( (JP:4577) ) has issued an update.

Daito Pharmaceutical has completed a share repurchase program authorized under its Articles of Incorporation and Article 459, Paragraph 1 of the Companies Act, buying back a total of 1,000,000 common shares for approximately 1.34 billion yen. The final tranche, executed between April 1 and April 22, 2026 via market purchases on the Tokyo Stock Exchange, involved 116,800 shares for about 163.9 million yen, signaling management’s continued focus on shareholder returns and potential capital efficiency improvements.

The buyback, originally approved by the board in October 2025 with a ceiling of 1,000,000 shares and 1.5 billion yen, has now been fully executed below the authorized monetary limit. This completion may support the company’s share price, enhance earnings per share through a reduced share count, and underscores Daito Pharmaceutical’s intention to actively manage its capital structure in line with investor-focused policies.

More about Daito Pharmaceutical Co., Ltd.

Daito Pharmaceutical Co., Ltd. is a Japan-based pharmaceutical company listed on the Prime Market of the Tokyo Stock Exchange under securities code 4577. The company operates in the healthcare and life sciences sector, focusing on the development and manufacture of pharmaceutical products for the domestic market and potentially broader regional healthcare needs.

Average Trading Volume: 89,525

Technical Sentiment Signal: Buy

Current Market Cap: Yen40.62B

See more insights into 4577 stock on TipRanks’ Stock Analysis page.